Latest Sulfoxides Stories

FRAZER, Pa., July 31 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) announced today that Craig C. Phillips has been appointed as Vice President and General Manager of the Oncology Business Unit. In this role, Phillips will have responsibility for managing all aspects of the U.S. oncology business including Sales, Marketing and Medical Affairs. (Photo: http://www.newscom.com/cgi-bin/prnh/20090731/PH54744 ) "Since joining Cephalon two years ago, Craig has clearly demonstrated an...

FRAZER, Pa., June 30 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) requesting approval of NUVIGIL(R) (armodafinil) Tablets [C-IV] for the indication of improved wakefulness in patients with excessive sleepiness associated with jet lag disorder resulting from eastbound travel. Jet lag disorder is an acute condition that occurs when a person's internal...

FRAZER, Pa., June 19 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced results from a pivotal clinical trial of lestaurtinib (CEP-701) in patients with relapsed acute myelogenous leukemia (AML) expressing FLT3 activating mutations. The study was designed to show the benefit of lestaurtinib in this patient population when given in sequence with standard induction chemotherapy compared to those treated with standard induction chemotherapy alone. An analysis of the...

Data Show That NUVIGIL Improves Excessive Sleepiness Associated with Jet Lag Disorder FRAZER, Pa., June 10 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) presented results from a pivotal trial that showed NUVIGIL(R) (armodafinil) Tablets [C-IV] significantly improved wakefulness in people with excessive sleepiness associated with jet lag disorder. These phase three data were presented today at the SLEEP 2009 23rd Annual Meeting of the Associated Professional Sleep Societies...

The US Food and Drug Administration on Thursday released a list of a variety of drugs that it is currently testing for possible safety issues.The list contains two-dozen different drugs, which vary from treatment of sleep disorder to weight-loss.Pfizer Inc's Chantix, a drug aimed at helping people stop smoking, is among the drug varieties currently being monitored by the FDA. Regulators are seeking to determine whether or not the drug poses a possible risk of accidental injury or vision...

WILMINGTON, Del., June 2 /PRNewswire-FirstCall/ -- Two studies from AstraZeneca (NYSE: AZN) show that symptomatic gastroesophageal reflux disease (GERD) patients treated with NEXIUM(R) (esomeprazole magnesium) 20 mg daily experienced greater relief from nighttime heartburn and GERD-related sleep disturbances compared with patients taking placebo over four weeks(1). NEXIUM 20 mg is indicated for the treatment of heartburn and other symptoms associated with GERD. NEXIUM, in a class of drugs...

NUVIGIL Launch Enhanced by Robust Patient Access Programs FRAZER, Pa., June 1 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced that NUVIGIL(R) (armodafinil) Tablets [C-IV], a longer-lasting formulation of modafinil, is now available. NUVIGIL is indicated to improve wakefulness throughout the day for the millions of patients who struggle with excessive sleepiness associated with treated obstructive sleep apnea, shift work sleep disorder, also known as shift work...

FRAZER, Pa., May 22 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) announced today that the underwriters of its previously announced offering of $435 million in aggregate principal amount of 2.50% convertible senior subordinated notes due 2014 have exercised in full their over-allotment option to purchase $65 million of additional notes, bringing the total amount of the notes to be issued to $500 million. Completion of the notes offering, including the additional notes, is subject...

FRAZER, Pa., May 20 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) announced today that it intends to offer, subject to market and other conditions, $300 million of common stock and $350 million in aggregate principal amount of convertible senior subordinated notes due 2014 through two concurrent public offerings. Cephalon will grant the underwriters a 30-day option, solely to cover over-allotments, to purchase up to an additional $45 million of common stock, with respect to the...

Cephalon now has a relevant interest in more than 50 percent of Arana shares FRAZER, Pa., May 20 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) announced today that its wholly-owned subsidiary, Cephalon International Holdings, Inc., now has a relevant interest in 50.1 percent of Arana Therapeutics Limited's issued shares and has declared its Offer for the company free from all outstanding conditions. As a result, under the previously announced accelerated payment terms, Arana...